Review Article
Ablative Therapy for Esophageal Dysplasia and Early Malignancy: Focus on RFA
Table 3
Esophageal RFA results summary.
| Series | Mean/median length of BE (cm) | Mean/median number of treatments required | Follow-up interval (months) | Complete eradication of intestinal metaplasia (%) | Complete eradication of low-grade dysplasia (%) | Complete eradication of high-grade dysplasia (%) | Rates of progression | Complication rates (%) |
| Ganz et al., 2008 [28] | 6 | 1 | 12 | 54.3 | 80.4 | 90.2 | — | 0.7 | Fleischer et al., 2008 [37] | 3.2 | 1.5 | 30 | 97 | — | — | — | 0 | Shaheen et al., 2009 [29] | 5.3* | Up to 4 | 12 | 77.4 | 90.5 | 81.0 | 4 | 6.0 | Fleischer et al., 2010 [38] | 3.2 | 3.4 | 60 | 92 | — | — | — | 0 | Lyday et al., 2010 [30] | 3 | 1.8–2.1 | 20 | 77 | 100 | — | — | 1.1 |
|
|
5.3 is mean and for HGD, 4.6 for LGD.
|